Results 21 to 30 of about 5,801 (166)

Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro

Viruses, 2023
Porcine epidemic diarrhea virus (PEDV) is a swine coronavirus that is highly infectious and prone to variation. Vaccines derived from traditional PEDV strains provide less protection against PEDV-variant strains. Furthermore; there is a complex diversity
Zi-Xin Huang, Shu-Ting Zhou, Zhi-Biao Yang, Zhe Wang   +3 more
doaj   +1 more source

Molnupiravir: First Approval [PDF]

Drugs, 2022
Molnupiravir (Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback Biotherapeutics for the prevention and treatment of Coronavirus disease 2019 (COVID-19).
openaire   +2 more sources

Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat

Communications Medicine, 2023
Background The antiviral drug molnupiravir is an orally bioavailable prodrug of the nucleoside analog β-D-N4-hydroxycytidine (NHC), which is used to treat coronavirus disease 2019 (COVID-19).
Chun-Hao Chang, Wen-Ya Peng, Wan-Hsin Lee, Ling Yang, Tung-Yi Lin, Muh-Hwa Yang, Tung-Hu Tsai   +6 more
doaj   +1 more source

Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial

Frontiers in Pharmacology, 2023
Introduction: Randomized, controlled trials of molnupiravir in real-world use during the Omicron wave are scarce. The frequency of hospitalization and death is low, so further research is needed to confirm the virological efficacy of molnupiravir.Methods:
Yayun Liu, Shiyong Fan, Aijing Xu, Lingling Ge, Xinyu Wang, Xu Dong, Mingxiao Xu, Wenhan Fan, Wu Zhong, Xuesong Liang   +9 more
doaj   +1 more source

Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrierResearch in context

EBioMedicine, 2023
Summary: Background: Molnupiravir is an orally bioavailable prodrug of the nucleoside analogue β-D-N4-hydroxycytidine (NHC) and is used to treat coronavirus disease 2019 (COVID-19).
Chun-Hao Chang, Wen-Ya Peng, Wan-Hsin Lee, Tung-Yi Lin, Muh-Hwa Yang, Jeffrey W. Dalley, Tung-Hu Tsai   +6 more
doaj   +1 more source

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19

Viruses, 2023
Molnupiravir, a prodrug known for its broad antiviral activity, has demonstrated efficacy in animal models of COVID-19, prompting clinical trials, in which initial results indicated a significant effect against the disease.
Henrik Berg Rasmussen, Peter Riis Hansen
doaj   +1 more source

Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis

Antibiotics, 2023
Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is unknown. The goal of the current meta-analysis was to compare the real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 during the ...
Chienhsiu Huang, Tsung-Lung Lu, Lichen Lin   +2 more
doaj   +1 more source

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Vaccines, 2022
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and infected with variants different from those currently circulating.
Ivan Gentile, Riccardo Scotto, Nicola Schiano Moriello, Biagio Pinchera, Riccardo Villari, Emilia Trucillo, Luigi Ametrano, Ludovica Fusco, Giuseppe Castaldo, Antonio Riccardo Buonomo, Federico II COVID Team   +10 more
doaj   +1 more source

New analytical method development and validation for estimation of molnupiravir in bulk and tablet dosage form by RP-HPLC method [PDF]

Cellular, Molecular and Biomedical Reports, 2023
A new simple, selective, rapid, precise reversed-phase high-performance liquid chromatography method has been developed and validated for the estimation of Molnupiravir in bulk and its pharmaceutical dosage form.
Gandu Sravanthi, Kumara Gandla, Lalitha Repudi   +2 more
doaj   +1 more source

Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?

Therapeutic Advances in Drug Safety, 2022
Plain Language Summary Could natural plant pigment (chlorophyll) derivatives (chlorophyllins) improve the safety of the antiviral Molnupiravir, used to treat COVID-19 disease?
Nicole F. Clark, Andrew W. Taylor-Robinson, Kirsten Heimann   +2 more
doaj   +1 more source